Retatrutide vs Epithalon
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Epithalon (Epitalon). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Epithalon Epitalon, Epithalone |
|---|---|---|
| FDA Status | Phase 3 (NDA expected late 2026) | Not submitted |
| Category | Weight Loss | Anti-Aging |
| Primary Use | Obesity and weight management | Anti-aging and longevity research |
| Weight Loss % | 28.7% | N/A |
| Monthly Cost | $1,200 - $1,500/mo | $40 - $80/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 5-10mg per cycle (10-20 days, 2-3x per year) |
| Frequency | Weekly | Cyclical |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend cellular lifespan |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Phase 3 | N/A |
Key Differences
- 1Retatrutide has clinical weight loss data (28.7%), while Epithalon is not primarily indicated for weight loss.
- 2Epithalon is generally more affordable ($40 - $80/mo) compared to Retatrutide ($1,200 - $1,500/mo).
- 3Retatrutide is dosed weekly, while Epithalon is cyclical.
- 4Retatrutide has high-quality evidence, while Epithalon has emerging-quality evidence.
- 5They belong to different categories: Retatrutide (Weight Loss) vs Epithalon (Anti-Aging).
Which Is Better For...
Epithalon
More budget-friendly option with lower monthly costs
Epithalon
More convenient dosing schedule (cyclical)
Epithalon
Fewer commonly reported side effects
Retatrutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 (NDA expected late 2026) | Eli Lilly |
| Epithalon | $40 - $80/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Epithalon works via Tetrapeptide that may activate telomerase enzyme to lengthen telomeres and potentially extend. They differ in FDA approval status, efficacy data, and cost.
Retatrutide has demonstrated 28.7% average weight loss in clinical trials. Epithalon is not primarily used for weight loss.
Retatrutide typically costs $1,200 - $1,500/mo, while Epithalon costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). Epithalon is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Epithalon include Injection site reactions, Mild drowsiness, Vivid dreams. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideEpithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) researched primarily in Russia for its potential anti-aging properties. The proposed mechanism involves activation of telomerase, an enzyme that...
View Full Epithalon GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Epithalon should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.